Postprint version. Published in The Journal of Orthopaedic Science, Volume 16, January 25, 2011, pages 93-98.
The definitive version is available at https://doi.org/10.1007/s00776-010-0016-0.
Objective: The purpose of this study was to evaluate the effect of Cox-2 administration on direct (primary) fracture healing.
Methods: A transverse tibial osteotomy was created in adult male rabbits and rigidly fixed in compression using a 2.7-mm dynamic compression plate. Animals were randomized to receive either rofecoxib (12.5 mg orally per day) or placebo. Animals were killed at 4 weeks and fracture healing assessed by mechanical testing.
Results: There were no significant differences between the control and Cox-2 treated animals in terms of mechanical strength at 4 weeks. There was a high complication rate of peri-implant fractures during the daily medication administration.
Conclusion: The immediate administration of a Cox-2 specific inhibitor did not impair primary (direct) bone healing at the dose administered in this rabbit tibial osteotomy model.
Biomedical Engineering and Bioengineering